Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance

Anticancer Research

Volumn 18, Issue 4 C, 1998, Pages 3017-3020

  Caffrey, Paula B ^a   Frenkel, Gerald D ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Drug resistance; Glutathione; Melphalan; Ovarian tumors; Selenite

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CISPLATIN; GLUTATHIONE; INORGANIC SALT; MELPHALAN; SELENITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CROSS RESISTANCE; DRUG RESISTANCE; FEMALE; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; OVARY TUMOR; PRIORITY JOURNAL; TUMOR RESISTANCE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CISPLATIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; GLUTATHIONE; HUMANS; MELPHALAN; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; SODIUM SELENITE; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031814729     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Ayash LJ, Herman TS and Frei E: Cancer chemotherapy: clinical evidence for drug resistance. In: Drug Resistance and Oncology (Teicher B ed.), Marcel Dekker, 1993, pp. 617-635.
2. Kellen JA: Mechanisms of multidrug resistance. In: Alternative Mechanisms of Multidrug Resistance in Cancer (Kellen JA ed.) Birkhauser, 1995, pp. 1-30.
3. Tew KD, Houghton PJ and Houghton JA: Preclinical and Clinical Modulation of Anticancer Drugs. CRC Press, 1993, pp. 13-77.
4. Combs GF Jr and Combs SB: The Role of Selenium in Nutrition (Combs GF Jr and Combs S.B, eds). San Diego, Academic Press, 1986, pp 413-461.
5. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL, Park HK, Sanders BB, Smith CL and Taylor JR: Effects of Se supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. JAMA 276: 1957-63, 1996.
6. Caffrey PB and Frenkel GD: Selenite cytotoxicity in multi-drug resistant and non- resistant human ovarian tumor cells. Caner Res 52: 4812-4816, 1992.
7. Caffrey PB and Frenkel GD: The development of drug resistance by tumor cells in vivo is accompanied by the development of sensitivity to selenite. Can Lett 81: 59-65, 1994.
8. Caffrey PB and Frenkel GD: Sensitivity of melphalan-resistant tumors to selenite in vivo. Caner Lett 121: 177-180, 1997.
9. Caffrey PB, Zhu, M and Frenkel GD: Prevention of the development of melphalan resistance in vitro by selenite. Submitted for publication.
10. Caffrey PB, Zhang Y and Frenkel GD: Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in vivo. Anticancer Res 18: 3021-3026, 1998
11. Caffrey PB and Frenkel GD: Inhibition of cell colony formation by selenite: involvement of glutathione. Molecular Pharmacol 39: 281-284, 1991.
12. Meister A: Metabolism and function of glutathione, In: Coenzymes and Cofactors. Glutathione: Chemical, Biochemical and Medical Aspects. (Dolphin D, Poulson R and Avramovic O, eds.) New York, Wiley, 1989 Part A, pp.367-474.
13. Yao K, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
14. Hissin PJ and Hilf R: A fluorometric method for determination of oxidized and reduced glutathione in tissues. Analytical Biochem 74: 214-226, 1976.